Mitochondria and Antioxidant Targeted Therapeutic Strategies for Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Oxidative stress and mitochondrial dysfunction are important features present in Alzheimer's disease (AD). They appear early and contribute to disease progression, both in human postmortem AD brains as well as in transgenic AD mouse brains. For this reason, targeting oxidative stress and mitochondria in AD may lead to the development of promising therapeutic strategies. Several exogenous antioxidant compounds have been tested and found beneficial in transgenic AD mice, such as vitamins and spices. However, their efficacy was much more modest in human trials. More recently, new strategies have been elaborated to promote endogenous antioxidant systems. Different pathways involved in oxidative stress response have been identified. Compounds able to upregulate these pathways are being generated and tested in animal models of AD and in human patients. Upregulation of antioxidant gene expression was beneficial in mice, giving hope for future avenues in the treatment of AD and other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577 · cited 1×
“analysis, focused on vitamin E, combined 19 clinical trials (135967 participants) [80].”
BackgroundA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“ease Cooperative Study (ADCS) published a doubleblind, placebo-controlled, randomized, multicenter trial of deprenyl and vitamin E [60].”
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 2×
“In vitro and in vivo, curcumin also reduced Aβ aggregation [51].”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 2×
“trotyrosine [2] are markedly augmented in AD patients”
BackgroundProfound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“5), there are already sufficiently many plaques and tangles for a neuropathologic diagnosis of AD, and 50% decreases in entorhinal cortex layer II neurons [66,67].”
BackgroundMoi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607 · cited 1×
“the NFE2L2 gene [99].”
Lim, G. P., Chu, T., Yang, F., Beech, W., Frautschy, S. A., & Cole, G. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08370.2001 · Cited by 1,530
The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses
Li, Z., Okamoto, K.-I., Hayashi, Y., & Sheng, M. (2004) · Cell · doi:10.1016/j.cell.2004.11.003 · Cited by 1,498 · cited 1×
“Conversely, increasing dendritic mitochondrial content or mitochondrial activity increased the number and plasticity of spines and synapses [24].”
BackgroundMild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“Hirai and colleagues found that in AD brains, neurons with increased oxidative damage had altered mitochondrial DNA and cytochrome oxidase levels [20].”
BackgroundImpaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104 · cited 1×
“At a young age and prior to the appearance of amyloid deposition, transgenic AD mice displayed increased levels of H2O2 and decreased levels of cytochrome oxidase [25].”
BackgroundS-Nitrosylation of Drp1 Mediates β-Amyloid-Related Mitochondrial Fission and Neuronal Injury
Cho, D.-H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z., & Lipton, S. A. (2009) · Science · doi:10.1126/science.1171091 · Cited by 1,092
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T., & Brinton, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903563106 · Cited by 940 · cited 1×
“presenilin 1 (PS1), and tau mutations [27].”
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007176.pub2 · Cited by 924
Praticò, D., Uryu, K., Leight, S., Trojanoswki, J. Q., & Lee, V. M.-Y. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04183.2001 · Cited by 777 · cited 1×
“This was observed prior to the appearance of amyloid plaques [15,16] and”
BackgroundLannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Morris, M. C. (2002) · JAMA · doi:10.1001/jama.287.24.3230 · Cited by 678 · cited 1×
“In a prospective, communitybased study of 815 non-demented subjects [76], vitamin E from food, but not from supplements, was associated with decreased incidence of AD in the highest quintile of vitamin E intake, a protective effect seen only among subjects not carrying an apolipoprotein E ε4 allele.”
BackgroundTriterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637 · cited 2×
“Induction of the Nrf2/ARE pathway by TPs is due to disruption of the binding between Nrf2 and Keap1, allowing Nrf2 to translocate to the nucleus [107].”
BackgroundNeuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596
Evidence of increased oxidative damage in subjects with mild cognitive impairment
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., & Markesbery, W. R. (2005) · Neurology · doi:10.1212/01.wnl.0000156156.13641.ba · Cited by 539
Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease
Lovell, M. A., & Markesbery, W. R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm821 · Cited by 515
Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Hauptmann, S., Scherping, I., Dröse, S., Brandt, U., Schulz, K. L., Jendrach, M., Leuner, K., Eckert, A., & Müller, W. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.005 · Cited by 469
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414 · cited 1×
“In the Washington Heights-Inwood Columbia Aging study of 980 non-demented subjects [77], intake of vitamin C and carotenes, or vitamin E in supplemental or dietary (nonsupplemental) forms, was not associated with decreased incidence of AD.”
BackgroundEfficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau
Melov, S., Adlard, P. A., Morten, K., Johnson, F., Golden, T. R., Hinerfeld, D., Schilling, B., Mavros, C., Masters, C. L., Volitakis, I., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000536 · Cited by 363
Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease
Resende, R., Moreira, P. I., Proença, T., Deshpande, A., Busciglio, J., Pereira, C., & Oliveira, C. R. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.012 · Cited by 343
Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease
Morris, M. C., Beckett, L. A., Scherr, P. A., Hebert, L. E., Bennett, D. A., Field, T. S., & Evans, D. A. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199809000-00001 · Cited by 332
Association of vitamin E and C supplement use with cognitive function and dementia in elderly men
Masaki, K. H., Losonczy, K. G., Izmirlian, G., Foley, D. J., Ross, G. W., Petrovitch, H., Havlik, R., & White, L. R. (2000) · Neurology · doi:10.1212/wnl.54.6.1265 · Cited by 330
Liby, K., Hock, T., Yore, M. M., Suh, N., Place, A. E., Risingsong, R., Williams, C. R., Royce, D. B., Honda, T., Honda, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4539 · Cited by 283 · cited 1×
“3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), have been identified as potent pharmacological inducers of the Nrf2/ARE signaling pathway in vitro and in vivo [106,107].”
BackgroundNicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Esposito, L., Raber, J., Kekonius, L., Yan, F., Yu, G.-Q., Bien-Ly, N., Puoliväli, J., Scearce-Levie, K., Masliah, E., & Mucke, L. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0482-06.2006 · Cited by 254
Massaad, C. A., Washington, T. M., Pautler, R. G., & Klann, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902714106 · Cited by 223 · cited 1×
“and improved memory deficit at various ages [39].”
High-dose antioxidant supplements and cognitive function in community-dwelling elderly women
Grodstein, F., Chen, J., & Willett, W. C. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.4.975 · Cited by 214 · cited 2×
“In the Nurses’ Health Study [72], long term current users (14968 community-dwelling wom- en) of vitamin E with vitamin C had significantly better global cognitive test scores than subjects who had never used either.”
Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162 · cited 1×
“volved 92–450 subjects [83–85], and suggested dosedependent, beneficial effects on cognition and slowing of disease progression for up to 2 years.”
BackgroundIdebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
A Controlled Study of 2 Doses of Idebenone in the Treatment of Alzheimer’s Disease
Weyer, G., Babej-Dölle, R. M., Hadler, D., Hofmann, S., & Herrmann, W. M. (2008) · Neuropsychobiology · doi:10.1159/000119366 · Cited by 120 · cited 1×
“volved 92–450 subjects [83–85], and suggested dosedependent, beneficial effects on cognition and slowing of disease progression for up to 2 years.”
BackgroundSupplemental Use of Antioxidant Vitamins and Subsequent Risk of Cognitive Decline and Dementia
Maxwell, C. J., Hicks, M. S., Hogan, D. B., Basran, J., & Ebly, E. M. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000085074 · Cited by 105 · cited 3×
“In the Honolulu-Asia Aging Study [69], vitamin E and vitamin C use was determined in 3385 Japanese American men, and 3–10 years later cognitive status was classified as AD, vascular dementia, mixed/other dementia, low test scores without dementia, or cognitively intact.”
Mendelsohn, A. B., Belle, S. H., Stoehr, G. P., & Ganguli, M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009556 · Cited by 88 · cited 1×
“In the Monongahela Valley Independent Elders Survey of 1059 subjects [75], intake of antioxidant supplements (vitamins A, C, E, β-carotene, zinc, and selenium) was initially associated with better cognitive performance in univariate analyses.”
Gutzmann, H., Kühl, K.-P., Hadler, D., & Rapp, M. A. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-19833 · Cited by 85
Cited by
Mechanism of Oxidative Stress in Neurodegeneration
Gandhi, S., & Abramov, A. Y. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/428010 · Cited by 960
Antioxidant Therapies for Alzheimer's Disease
Feng, Y., & Wang, X. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/472932 · Cited by 379
β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease
Gouras, G. K., Olsson, T. T., & Hansson, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0313-y · Cited by 325
Miller, M. W., & Sadeh, N. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.111 · Cited by 288
Mitochondria and Reactive Oxygen Species: Physiology and Pathophysiology
Bolisetty, S., & Jaimes, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14036306 · Cited by 273
Metadata
- Authors
- Dumont, M., Lin, M. T., & Beal, M. F.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-06-03
- Volume
- 20
- Issue
- s2
- Pages
- S633-S643
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1529222933
- Cited by
- 84
- References
- 46
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.